WILMINGTON, Mass., December 01, 2022--Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles River’s data integrity compliant, fully robotic instrument, capable of processing both undiluted or complex, serial dilutions for water, in-process, and final product testing via Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology in a fully enclosed system. Pow
WILMINGTON, Mass., November 28, 2022--Charles River recently opened its first location in Chicago, expanding contract vivarium space for the biopharmaceutical industry in Illinois.
WILMINGTON, Mass., November 14, 2022--Charles River Laboratories To Present At November Investor Conferences